Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen

Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet